➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Medtronic
Boehringer Ingelheim
Mallinckrodt
Colorcon

Last Updated: July 29, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207923


Email this page to a colleague

« Back to Dashboard

NDA 207923 describes SEEBRI, which is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are twelve patents protecting this drug. Additional details are available on the SEEBRI profile page.

The generic ingredient in SEEBRI is glycopyrrolate. There are seventeen drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
Summary for 207923
Tradename:SEEBRI
Applicant:Novartis
Ingredient:glycopyrrolate
Patents:12
Formulation / Manufacturing:see details
Pharmacology for NDA: 207923
Mechanism of ActionCholinergic Antagonists
Medical Subject Heading (MeSH) Categories for 207923
Suppliers and Packaging for NDA: 207923
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SEEBRI glycopyrrolate POWDER;INHALATION 207923 NDA Sunovion Pharmacueticals Inc. 63402-815 63402-815-06 1 BLISTER PACK in 1 CARTON (63402-815-06) > 6 CAPSULE in 1 BLISTER PACK (63402-815-01) > 1 CAPSULE in 1 CAPSULE
SEEBRI glycopyrrolate POWDER;INHALATION 207923 NDA Sunovion Pharmacueticals Inc. 63402-815 63402-815-12 2 BLISTER PACK in 1 CARTON (63402-815-12) > 6 CAPSULE in 1 BLISTER PACK (63402-815-02) > 1 CAPSULE in 1 CAPSULE

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:POWDER;INHALATIONStrength15.6MCG/INH
Approval Date:Oct 29, 2015TE:RLD:Yes
Patent:⤷  Try it FreePatent Expiration:Apr 9, 2021Product Flag?Substance Flag?Delist Request?
Patented Use:LONG-TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Patent:⤷  Try it FreePatent Expiration:Jun 27, 2021Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Try it FreePatent Expiration:Apr 9, 2021Product Flag?Substance Flag?Delist Request?
Patented Use:LONG-TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Expired US Patents for NDA 207923

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 ⤷  Try it Free ⤷  Try it Free
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 ⤷  Try it Free ⤷  Try it Free
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 ⤷  Try it Free ⤷  Try it Free
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 ⤷  Try it Free ⤷  Try it Free
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 ⤷  Try it Free ⤷  Try it Free
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 ⤷  Try it Free ⤷  Try it Free
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Johnson and Johnson
Baxter
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.